» Articles » PMID: 38892787

Exploring the Perioperative Use of DOACs, off the Beaten Track

Abstract

A notable increase in direct oral anticoagulant (DOAC) use has been observed in the last decade. This trend has surpassed the prescription of vitamin K antagonists (VKAs) due to the absence of the need for regular laboratory monitoring and the more favorable characteristics in terms of efficacy and safety. However, it is very common that patients on DOACs need an interventional or surgical procedure, requiring a careful evaluation and a challenging approach. Therefore, perioperative anticoagulation management of patients on DOACs represents a growing concern for clinicians. Indeed, while several surgical interventions require temporary discontinuation of DOACs, other procedures that involve a lower risk of bleeding can be conducted, maintaining a minimal or uninterrupted DOAC strategy. Therefore, a comprehensive evaluation of patient characteristics, including age, susceptibility to stroke, previous bleeding complications, concurrent medications, renal and hepatic function, and other factors, in addition to surgical considerations, is mandatory to establish the optimal discontinuation and resumption timing of DOACs. A multidisciplinary approach is required for managing perioperative anticoagulation in order to establish how to face these circumstances. This narrative review aims to provide physicians with a practical guide for DOAC perioperative management, addressing the most controversial issues.

Citing Articles

Acute Coronary Syndrome in Elderly Patients: How to Tackle Them?.

Luca F, Andreotti F, Rao C, Pelaggi G, Nucara M, Ammendolea C J Clin Med. 2024; 13(19).

PMID: 39407995 PMC: 11478011. DOI: 10.3390/jcm13195935.


Multidisciplinary Approach in Atrial Fibrillation: As Good as Gold.

Luca F, Abrignani M, Oliva F, Canale M, Parrini I, Murrone A J Clin Med. 2024; 13(16).

PMID: 39200763 PMC: 11354619. DOI: 10.3390/jcm13164621.

References
1.
Godier A, Dincq A, Martin A, Radu A, Leblanc I, Antona M . Predictors of pre-procedural concentrations of direct oral anticoagulants: a prospective multicentre study. Eur Heart J. 2017; 38(31):2431-2439. DOI: 10.1093/eurheartj/ehx403. View

2.
Birnie D, Healey J, Wells G, Ayala-Paredes F, Coutu B, Sumner G . Continued vs. interrupted direct oral anticoagulants at the time of device surgery, in patients with moderate to high risk of arterial thrombo-embolic events (BRUISE CONTROL-2). Eur Heart J. 2018; 39(44):3973-3979. DOI: 10.1093/eurheartj/ehy413. View

3.
Zhu W, He W, Guo L, Wang X, Hong K . The HAS-BLED Score for Predicting Major Bleeding Risk in Anticoagulated Patients With Atrial Fibrillation: A Systematic Review and Meta-analysis. Clin Cardiol. 2015; 38(9):555-61. PMC: 6490831. DOI: 10.1002/clc.22435. View

4.
Rossini R, Pecora D, Ferlini M, Gentile F, Moschini L, Pedrinazzi C . [Why NAO: Know How. Why and how to choose the new oral anticoagulant in cardiological clinical practice]. G Ital Cardiol (Rome). 2015; 16(3):161-74. DOI: 10.1714/1820.19826. View

5.
Boriani G, Corradini P, Cuneo A, Falanga A, Foa R, Gaidano G . Practical management of ibrutinib in the real life: Focus on atrial fibrillation and bleeding. Hematol Oncol. 2018; 36(4):624-632. DOI: 10.1002/hon.2503. View